Corporate News - Beijing Beilu Pharmaceutical Co., Ltd.

CPhl China 2023 Invitation

2023/04/20

Iohexol from Beilu Pharma's holding subsidiary Zhejiang Hichi Pharmaceutical Corporation Limited has been registered with CDSCO

2023/03/07

Recently, Zhejiang Haichang Pharmaceutical Co., Ltd., a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received a registration certificate for its active pharmaceutical ingredient product from ...

VIEW_MORE

Beilu Pharmaceutical has Won the '2022 China Top 500 Corporate Philanthropy' Award!

2023/02/24

Recently, the "Wealth and Responsibility - Values of Enterprises" 2022 China Top 500 Charity List Conference was held in Chongqing. Since its inclusion in 2021, Beilu Pharmaceutical has been...

VIEW_MORE

Beilu was Awarded the Title of A-class enterprise for safety production

2023/01/31

Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this awa...

VIEW_MORE

Beilu Pharmaceutical Intends to Establish a Wholly-owned Subsidiary in Hong Kong

2022/12/27

In order to further expand overseas markets and meet the needs of the company's strategic development, Beilu Pharmaceutical intends to establish a wholly-owned subsidiary in Hong Kong.Actively exp...

VIEW_MORE

Beilu Yikang, the R&D Subsidiary of Beilu Pharmaceutical, Was Officially Launched

2022/10/12

"Building a multi-level R&D system and actively creating a second growth curve" is the development strategy of the company, and also one of the key tasks of the company in the next few y...

VIEW_MORE

Beilu Pharma Established a Wholly-owned R&D Subsidiary

2022/09/06

Taking the "Top 100 Chinese Pharmaceutical Enterprises" as the medium and long-term goal, Beilu Pharma has decided to choose not only the Contrast Agent field, Central Nervous System (Propri...

VIEW_MORE